Polypharmacy is Associated with Co-morbidity and Predicts outcome in Patients undergoing Index Pulmonary Hypertension Assessment

2018 ◽  
Vol 07 (03) ◽  
Author(s):  
Michael McGee ◽  
Avedis Ekmejian ◽  
Seshika Ratwatte ◽  
Allan Davies ◽  
Stuart Turner ◽  
...  
2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Elodie Roels ◽  
Aline Fastrès ◽  
Anne-Christine Merveille ◽  
Géraldine Bolen ◽  
Erik Teske ◽  
...  

Abstract Background Pulmonary hypertension (PH) is a known co-morbidity in West Highland white terriers (WHWTs) affected with canine idiopathic pulmonary fibrosis (CIPF). The pulmonary vein-to-right pulmonary artery ratio (PV/PA) has recently been described for the detection of pre-capillary PH in dogs. The objective of the present study was to estimate the prevalence of PH at diagnostic, in WHWTs affected with CIPF, by using PV/PA, in comparison with a group of healthy breed-matched controls (CTRLs). Additional study objective was to explore whether the presence of PH at initial diagnosis of CIPF impacted survival time in dogs treated with sildenafil. Results Twenty-five client-owned WHWTs presented with CIPF and 19 CTRLs were included in the study. PV/PA in either two-dimensional mode (2D) or time-motion mode or both were measured from cineloops in each dog. Dogs were classified according to PV/PA value into non/mild PH (PV/PA measured in 2D ≥ 0.7) or moderate/severe PH (PV/PA < 0.7). Survival data of WHWTs affected with CIPF were extracted from medical record to assess association between presence of PH at diagnosis and outcome. 60 % overall prevalence for moderate/severe PH was estimated in this cohort of WHWTs presented with CIPF vs. 5 % in CTRLS (P = 0.0002). The presence of moderate/severe PH at initial presentation was not associated with survival. Conclusions Results of the present study confirm a high prevalence of PH at diagnosis in WHWTs affected with CIPF and highlight the utility of PV/PA as a non-invasive surrogate for assessment of PH in this population.


2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Grégoire Ruffenach ◽  
Jason Hong ◽  
Mylène Vaillancourt ◽  
Lejla Medzikovic ◽  
Mansoureh Eghbali

AbstractPulmonary hypertension (PH) developing secondarily in pulmonary fibrosis (PF) patients (PF-PH) is a frequent co-morbidity. The high prevalence of PH in PF patients is very concerning since the presence of PH is a strong predictor of mortality in PF patients. Until recently, PH was thought to arise solely from fibrotic destruction of the lung parenchyma, leading to hypoxic vasoconstriction and loss of vascular bed density. Thus, potential cellular and molecular dysregulation of vascular remodeling as a driver of PF-PH has been under-investigated. The recent demonstrations that there is no correlation between the severity of the fibrosis and development of PH, along with the finding that significant vascular histological and molecular differences exist between patients with and without PH have shifted the etiological paradigm of PF-PH. This review aims to provide a comprehensive translational overview of PH in PF patients from clinical diagnosis and outcome to the latest understanding of the histology and molecular pathophysiology of PF-PH.


2017 ◽  
Vol 7 (3) ◽  
pp. 674-683 ◽  
Author(s):  
Jared M. O’Leary ◽  
Tufik R. Assad ◽  
Meng Xu ◽  
Kelly A. Birdwell ◽  
Eric Farber-Eger ◽  
...  

Pulmonary hypertension (PH) is common in patients with chronic kidney disease (CKD) and associated with increased mortality but the hemodynamic profiles, clinical risk factors, and outcomes have not been well characterized. Our objective was to define the hemodynamic profile and related risk factors for PH in CKD patients. We extracted clinical and hemodynamic data from Vanderbilt’s de-identified electronic medical record on all patients undergoing right heart catheterization during 1998–2014. CKD (stages III–V) was defined by estimated glomerular filtration rate thresholds. PH was defined as mean pulmonary pressure ≥ 25 mmHg and categorized into pre-capillary and post-capillary according to consensus recommendations. In total, 4635 patients underwent catheterization: 1873 (40%) had CKD; 1518 (33%) stage 3, 230 (5%) stage 4, and 125 (3%) stage 5. PH was present in 1267 (68%) of these patients. Post-capillary (n = 965, 76%) was the predominant PH phenotype among CKD patients versus 302 (24%) for pre-capillary ( P < 0.001). CKD was independently associated with pulmonary hypertension (odds ratio = 1.4, 95% confidence interval = 1.18–1.65). Mortality among CKD patients rose with worsening stage and was significantly increased by PH status. PH is common and independently associated with mortality among CKD patients referred for right heart catheterization. Post-capillary was the most common etiology of PH. These data suggest that PH is an important prognostic co-morbidity among CKD patients and that CKD itself may have a role in the development of pulmonary vascular disease in some patients.


Author(s):  
Anouk Pels ◽  
Wes Onland ◽  
Rolf M. F. Berger ◽  
Arno F. J. van Heijst ◽  
Enrico Lopriore ◽  
...  

AbstractThe aim was to reflect on the unexpected finding of persistent pulmonary hypertension of the neonate (PPHN) and pulmonary hypertension in infants born within the Dutch STRIDER trial, its definition and possible pathophysiological mechanisms. The trial randomly assigned pregnant women with severe early-onset fetal growth restriction to sildenafil 25 mg three times a day versus placebo. Sildenafil use did not reduce perinatal mortality and morbidity, but did result in a higher rate of neonatal pulmonary hypertension (PH). The current paper reflects on the used definition, prevalence, and possible pathophysiology of the data on pulmonary hypertension. Twenty infants were diagnosed with pulmonary hypertension (12% of 163 live born infants). Of these, 16 infants had PPHN shortly after birth, and four had pulmonary hypertension associated with sepsis or bronchopulmonary dysplasia. Four infants with PPHN in the early neonatal period subsequently developed pulmonary hypertension associated with bronchopulmonary dysplasia in later life. Infants with pulmonary hypertension were at lower gestational age at delivery, had a lower birth weight and a higher rate of neonatal co-morbidity. The infants in the sildenafil group showed a significant increase in pulmonary hypertension compared to the placebo group (relative risk 3.67; 95% confidence interval 1.28 to 10.51, P = 0.02).Conclusion: Pulmonary hypertension occurred more frequent among infants of mothers allocated to antenatal sildenafil compared with placebo. A possible pathophysiological mechanism could be a “rebound” vasoconstriction after cessation of sildenafil. Additional studies and data are necessary to understand the mechanism of action. What is Known:• In the Dutch STRIDER trial, persistent pulmonary hypertension in the neonate (PPHN) was more frequent among infants after antenatal sildenafil exposure versus placebo. What is New:• The current analysis focuses on the distinction between PPHN and pulmonary hypertension associated with sepsis or bronchopulmonary dysplasia and on timing of diagnosis and aims to identify the infants at risk for developing pulmonary hypertension.• The diagnosis pulmonary hypertension is complex, especially in infants born after severe early-onset fetal growth restriction. The research field could benefit from an unambiguous consensus definition and standardized screening in infants at risk is proposed.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3782-3782
Author(s):  
Claudia R. Morris ◽  
Ward Hagar ◽  
Jennifer Gardner ◽  
Jennifer Michlitsch ◽  
Elliott Vichinsky

Abstract Pulmonary hypertension (PH) is an important co-morbidity in sickle cell disease (SCD). Despite increasing research in adults, the prevalence and implication of this condition in children is unknown. Charts of 362 SCD patients followed at Children’s Hospital & Research Center Oakland were reviewed in order to determine clinical associations of PH in adults and children with SCD. Patients with underlying lung abnormalities or those on chronic transfusions were more likely to have echocardiograms in this cohort, however the diagnosis of PH was often unrecognized. Of the 110 pediatric patients, 61 were screened by an echocardiogram with 15 meeting echocardiogram criteria for PH (24.6%.) The ages of children with PH ranged from 7 to 17 years (mean 12.7±3 years). Of the 252 adults, 148 were screened and 81 were considered to have PH (53.7%). Only 52% of patients with PH based on abnormal echocardiography were identified by a clinician as having PH, and although 38 (46.9%) were receiving chronic transfusions, only 4% were specifically treated for PH. Of the 15 children with PH, only 9 carried that diagnosis of PH in their charts, and none were on therapy geared towards PH. A different clinical phenotype for PH in adults versus children was identified. Associations with PH for adults included age, renal and lung disease, Hepatitis C, chronic transfusions, and a history of acute chest syndrome (ACS), with ACS being protective (OR [95% CI]: 0.40 [0.16 – 1.00], p &lt;0.05). For children, a history of sepsis (7.00 [1.29 – 39.7], p= 0.01), ACS (8.2 [1.04 – 367], p&lt;0.05) or obstructive lung disease suggestive of asthma (4.70 [1.4 – 16.4], p=0.01) was associated with PH, possibly reflecting distinct aspects of endothelial dysfunction. Logistic regression of their 3 significant univariant variables found that only a history of sepsis (adjusted OR 2.16; 95% CI 1.2–28.3, p=0.031) remained significant, with the history of asthma or obstructive lung disease nearly so (adjusted OR 1.86; 95% CI 0.93 −14.9, p=0.062) with an area of the receiver operator curve of 0.80. It is well documented that asthma and ACS are associated with complications in SCD, and these data demonstrate an association of these conditions with PH in children with SCD as well. This is the first report to identify a relationship between bacteremia or sepsis and PH in children with SCD. Asthma, sepsis and ACS are all conditions associated with arginine dysregulation and low nitric oxide bioavailability, a shared mechanism with hemolysis-associated PH. PH is a common complication in SCD that affects children as well as adults. The diagnosis is often missed, even with echocardiographic evidence of PH, likely related to lower pulmonary pressures occurring in patients with SCD, compared to levels typically associated with PH. Children with PH have a different profile of complications than adults with PH, suggesting alternate mechanisms of disease pathogenesis in children that may require different screening methods and potentially even different treatment approaches. Since PH is associated with high mortality and morbidity, universal screening by Doppler echocardiagram should target children as well as adults. Increased awareness is essential to identify patients at risk, and new therapies are critically needed.


Author(s):  
Abhishek Sharma ◽  
Yogesh Tripathi ◽  
Berendra Yadav ◽  
Rinku Garg

Chronic obstructive pulmonary disease (COPD) characterized by interminable air flow limitation that is not fully reversible COPD includes chronic bronchitis, emphysema, and chronic asthmatic bronchitis.  Chronic obstructive pulmonary disease as a complex disease with various systemic manifestations and one of the co-morbidity linked with COPD is cardiovascular disease.  Hypoxic vasoconstriction and alterations in pulmonary microvasculature, which are both observed in COPD patients, leads to an increase in pulmonary vascular resistance. As a result, this increase in right ventricular (RV) after load causes right ventricular remodeling, including chamber dilatation and wall hypertrophy and ultimately to functional deterioration.  The aim of this study to evaluate the right ventricular changes that develop secondary to COPD using GOLD guidelines and echocardiographic findings .This cross-sectional study involved 134 patients who presented to the pulmonary disease outpatient clinic with COPD. We assessed the right ventricular changes in COPD patients of different severity using echocardiography .COPD patients shown change in the right ventricular dimensions as the severity of COPD increases and right ventricular function as well.  It is also observed that frequency of pulmonary hypertension also increased as the severity of COPD increases. The study shows high prevalence of cardiac co-morbidities such as RV dysfunction and pulmonary hypertension in COPD patients. The severity of complications increases with severity of COPD and makes a linear relation. Keywords: Echocardiography, ECG, COPD


2018 ◽  
Vol 19 (8) ◽  
pp. 2224 ◽  
Author(s):  
Clovis Chabert ◽  
Saadi Khochbin ◽  
Sophie Rousseaux ◽  
Sylvie Veyrenc ◽  
Rebecca Furze ◽  
...  

Pulmonary hypertension is a co-morbidity, which strongly participates in morbi-mortality in patients with chronic obstructive pulmonary disease (COPD). Recent findings showed that bromodomain-containing proteins, in charge of reading histone acetylation, could be involved in pulmonary arterial hypertension. Our aim was to study the effect of I-BET151, an inhibitor of bromodomain and extra-terminal domain (BET), on the right ventricle hypertrophy and pulmonary hypertension, induced by a combination of chronic hypoxia and pulmonary inflammation, as the two main stimuli encountered in COPD. Adult Wistar male rats, exposed to chronic hypoxia plus pulmonary inflammation (CHPI), showed a significant right ventricle hypertrophy (+57%, p < 0.001), an increase in systolic pressure (+46%, p < 0.001) and in contraction speed (+36%, p < 0.001), when compared to control animals. I-BET151 treated animals (CHPI-iB) showed restored hemodynamic parameters to levels similar to control animals, despite chronic hypoxia plus exposure to pulmonary inflammation. They displayed lower right ventricle hypertrophy and hematocrit compared to the CHPI group (respectively −16%, p < 0.001; and −9%, p < 0.05). Our descriptive study shows a valuable effect of the inhibition of bromodomain and extra-terminal domain proteins on hemodynamic parameters, despite the presence of chronic hypoxia and pulmonary inflammation. This suggests that such inhibition could be of potential interest for COPD patients with pulmonary hypertension. Further studies are needed to unravel the underlying mechanisms involved and the net benefits of inhibiting adaptations to chronic hypoxia.


2001 ◽  
Vol 120 (5) ◽  
pp. A377-A377
Author(s):  
F BENJAMINOV ◽  
K SNIDERMAN ◽  
S SIU ◽  
P LIU ◽  
M PRENTICE ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document